MEKK3 and Survivin Expression in Cervical Cancer: Association with Clinicopathological Factors and Prognosis

siRNA-mediated Silencing of Survivin Inhibits Proliferation and Enhances Etoposide Chemosensitivity in Acute Myeloid Leukemia Cells

(2014) Hadi Karami et al.   Asian Pacific Journal of Cancer Prevention

Mitogen activated protein kinase kinase kinase 3 (MAP3K3/MEKK3) overexpression is an early event in esophageal tumorigenesis and is a predictor of poor disease prognosis

(2014) Raghibul Hasan et al.   BMC CANCER

Scoring System and Management Algorithm Assessing the Role of Survivin Expression in Predicting Progressivity of HPV Infections in Precancerous Cervical Lesions

(2013) Junita Indarti et al.   Asian Pacific Journal of Cancer Prevention

Oncostatin M receptor is a novel therapeutic target in cervical squamous cell carcinoma

(2013) Maria M Caffarel et al.   JOURNAL OF PATHOLOGY

Survivin promoter −31G/C (rs9904341) polymorphism and cancer susceptibility: a meta-analysis

(2011) Kshitij Srivastava et al.   MOLECULAR BIOLOGY REPORTS

MEKK3 expression correlates with nuclear factor κ B activity and with expression of antiapoptotic genes in serous ovarian carcinoma

(2009) Ajoy K. Samanta et al.   CANCER

MEKK3 is required for lysophosphatidic acid-induced NF-κB activation

(2009) Wenjing Sun et al.   CELLULAR SIGNALLING

PB1 Domain Interaction of p62/Sequestosome 1 and MEKK3 Regulates NF-κB Activation

(2009) Kazuhiro Nakamura et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MAP3Ks as central regulators of cell fate during development

(2008) Evisabel A. Craig et al.   DEVELOPMENTAL DYNAMICS

IAP-targeted therapies for cancer

(2008) E C LaCasse et al.   ONCOGENE